Should the use of omeprazole be allowed during equestrian competition?

Equine Vet J

School of Veterinary Sciences, Massey University, Palmerston North, New Zealand.

Published: July 2024

Background: Prioritising equine welfare, making evidenced-based policy, and consistent decision-making across sports are crucial to maintaining the social licence for equestrian sport. Regulations on the use of omeprazole during competition differ; all regulators argue that their rules prioritise welfare. This discrepancy is a matter of concern to the public and equestrian stakeholders.

Objectives: To apply Campbell's Ethical Framework for the use of Horses in Sport to the question: 'Should the use of omeprazole be allowed during equestrian competition?'

Study Design: A desk-based ethico-legal study.

Methods: Campbell's Ethical Framework for the Use of Horses in Sport was applied in a stepwise fashion: definition of the ethical question; analysis of the evidence base; consideration of stakeholders' interests; harm:benefit analysis; application of the three central tenets of the framework, and formulation of conclusions and recommendations.

Results: Stakeholders in equine sports have a variety of (frequently conflicting) interests; all of them share an interest in optimising equine welfare. The incidence of EGUS in competition horses is high. Omeprazole is a cornerstone treatment. There are currently discrepancies in regulation about the use of omeprazole during competitions. Recent evidence suggests that withholding omeprazole treatment for two clear days before competition allows the recurrence of squamous EGUS, whereas withholding treatment on the day of competition only does not have that effect.

Main Limitations: The current state of scientific knowledge about the use of omeprazole in horses. The analysis did not consider possible health and thus welfare effects of the out-of-competition treatment with omeprazole.

Conclusions: Based on recent scientific evidence, if horses are being treated with omeprazole outside of competition then treatment on the day of competition should be permitted on welfare grounds. Revision of regulations around the use of omeprazole during competition by governing bodies is necessary to safeguard the ethical use of horses in sport.

Download full-text PDF

Source
http://dx.doi.org/10.1111/evj.14129DOI Listing

Publication Analysis

Top Keywords

omeprazole competition
12
horses sport
12
omeprazole
9
omeprazole allowed
8
allowed equestrian
8
equine welfare
8
regulations omeprazole
8
campbell's ethical
8
ethical framework
8
framework horses
8

Similar Publications

In patients with gastroesophageal reflux disease (GERD) whose symptoms improve with acid-suppression therapy, on-demand treatment could constitute maintenance therapy. This study investigated the comparative efficacy and safety of on-demand tegoprazan and proton-pump inhibitor (PPI) therapy in GERD. From six university hospitals in the Daejeon-Chungcheong region, we enrolled patients with GERD who had experienced symptomatic improvement with acid-suppressive therapy and, using a randomization table, randomly allocated these participants to two groups: to receive either tegoprazan 50 mg + esomeprazole placebo or tegoprazan placebo + esomeprazole 20 mg, respectively.

View Article and Find Full Text PDF

Background: The efficacy of the 14-day esomeprazole-amoxicillin (EA) dual therapy in eradicating () has been widely discussed previously. Vonoprazan, a novel potassium-competitive acid blocker, presents rapid, potent, and long-lasting acid inhibitory effects compared to esomeprazole. However, there is currently a scarcity of direct comparisons between the 10-day vonoprazan-amoxicillin (VA) and the 14-day EA dual therapy for eradication.

View Article and Find Full Text PDF

Introduction: Proton pump inhibitors (PPIs) and potassium-competitive acid blockers (P-CABs) are widely used to manage gastric acid-related disorders by inhibiting hydrochloric acid (HCl) secretion from parietal cells in the stomach. Although PPIs are known to have anti-inflammatory properties beyond their role in inhibiting gastric acid secretion, research on P-CABs is lacking. In this study, we aimed to investigate whether all available P-CABs exhibit anti-inflammatory effects in gastroesophageal reflux-induced esophagitis and to elucidate the underlying mechanisms.

View Article and Find Full Text PDF

Background: Patients with erosive oesophagitis, and those with persistent symptomatic non-erosive gastro-oesophageal reflux disease, require long-term maintenance treatment with acid-suppressing agents.

Aim: To evaluate the safety of vonoprazan, a potassium-competitive acid blocker, in an integrated analysis of data from clinical trials in adults.

Methods: We included 14 clinical trials of vonoprazan conducted in multiple countries.

View Article and Find Full Text PDF
Article Synopsis
  • Gastric acid-related disorders like peptic ulcers and gastroesophageal reflux disease (GERD) are primarily caused by excessive stomach acid or bacterial infections, and can be treated with medications such as proton pump inhibitors (PPIs) and vonoprazan.
  • While PPIs work by irreversibly blocking the proton pump in stomach cells, vonoprazan inhibits acid secretion by targeting the potassium-competitive acid blocker receptor, making it one of the most effective options for GERD.
  • The review highlights various innovative micro/nano formulations of these medications, as well as the crucial role of imaging techniques like CT scans and endoscopy in diagnosing and managing these gastric acid disorders.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!